Imaging services provider Radiologix reported a net loss of $2.1 million, or 10¢ per diluted share, compared with net income of $276,000, or 2¢ per diluted share for the same period last year. Income from continuing operations excluding charges and a
Imaging services provider Radiologix reported a net loss of $2.1 million, or 10¢ per diluted share, compared with net income of $276,000, or 2¢ per diluted share for the same period last year. Income from continuing operations excluding charges and a gain on sale of operations rose, however, to $1 million, or 5¢ per diluted share, compared with $898,000, or 4¢ per diluted share in 2Q 2003. Earnings before interest, taxes, depreciation, and amortization (EBITDA) were $12.5 million for 2Q 2004, compared with $12.6 million for 2Q 2003. Adjusted EBITDA as a percentage of service fee revenue was 18.4% for the 2Q 2004, compared with 20.3% for 2Q 2003.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.